Pfizer's 95% Efficacy Is Exciting, Says Ginkgo Bioworks CEO

The transcript discusses Ginkgo Bioworks' role in bioengineering for vaccine distribution, focusing on the manufacturing and distribution challenges of mRNA vaccines like those from Pfizer and Moderna. It highlights the potential market availability of these vaccines and the importance of surveillance testing as an interim solution. The conversation also explores the future impact of mRNA technology on vaccine development and the specific manufacturing processes involved.

What role does surveillance testing play in managing the spread of the virus before vaccines are widely available?

In what ways could the new mRNA technology change future vaccine development?

What are the two main steps involved in the manufacturing process of mRNA vaccines?